Zeposia - (0.23, 0.46, and 0.92 mg ; Capsule)

Generic Name	Ozanimod Hydrochloride	Innovator	BRISTOL MYERS SQUIBB
Dosage	0.23, 0.46, and 0.92 mg ; Capsule	Branded US Sales	Less Than $1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	Less Than 5	Tentative Approvals	None
Final Approvals	None	Generic Launches	None
Indication	ZEPOSIA is a sphingosine 1-phosphate receptor modulator indicated for the treatment of: • Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. • Moderately to severely active ulcerative colitis (UC) in adults.
Complexities	Yes

Executive Summary

Patent Status

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
******* ******	*** \ *********	**** **, ****	*******	****	*** ****** **** ****
******	*** \ *********	**** **, ****	*******	****	*** ****** **** ****

Chronology Of Events